Get to know CLINDAGEL®         PRESCRIBE ONCE-DAILY CLINDAGEL WITH EASE1   USING THE VALEANT ACCESS PROGRAM Administered by Philidor Rx         $0 for eligible insured patients*       $75 self-pay option for cash-paying patients*         Free shipping: delivered right to patients’ doors       FOR MORE INFORMATION, OR TO PRESCRIBE, FAX 855-344-4347 OR EMAIL PHILIDOR Rx       Indication   CLINDAGEL® (clindamycin phosphate) gel, 1% is indicated for topical application in the treatment of acne. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate.   Important Safety Information   • CLINDAGEL is contraindicated in patients with a history of hypersensitivity to clindamycin or lincomycin, or a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.   • Orally and parenterally administered clindamycin has been associated with severe colitis (beginning up to several weeks following cessation of treatment), which may result in patient death.   • Diarrhea, bloody diarrhea, and pseudomembranous colitis have been reported with topical clindamycin. Discontinuation is recommended if diarrhea develops.   • CLINDAGEL should be used with caution in atopic individuals and in patients receiving neuromuscular blocking agents.   • CLINDAGEL should be used during pregnancy only if clearly needed.   • Orally and parenterally administered clindamycin has been reported in breast milk; because of the risk of adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, depending on the importance of the drug to the mother.   • The safety and effectiveness in children under 12 have not been established.     Click here for Prescribing Information.       References: 1. CLINDAGEL [package insert]. Cumberland, RI: Onset Dermatologics, LLC; 2014. 2. US Food and Drug Administration. Approved Drug Products With Therapeutic Equivalence Evaluations. 35th ed. Silver Spring, MD: US Food and Drug Administration; 2015. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436.pdf. Accessed May 27, 2015.     * Eligibility Criteria: This offer is only valid for patients with commercial insurance or cash-paying patients. Commercially insured patients whose insurance does not cover this drug and cash-paying patients will pay $75. Most commercially insured patients whose insurance covers this product will pay no more than $0 (after primary insurance and use of the patient access card). This offer is not valid for prescriptions reimbursed in whole or in part by Medicaid, Medicare (including Medicare Advantage [MA] and Part D plans), or any other federal or state programs (including VA, DOD, TRICARE, or any state prescription drug programs). Void where prohibited by law, taxed, or restricted. Void outside the United States. Valeant Pharmaceuticals reserves the right to rescind, revoke, or amend this offer at any time without notice. Philidor Rx does not participate in MA or Part D plans. The self-pay option is available to enrollees of such plans as an alternative to using their MA or Part D benefits, which, in some cases, may require prior authorization or a co-payment that exceeds the self-pay option price. MA and Part D patients should consult their plan benefits to determine whether the self-pay option is right for them.   You have the right to opt out of receiving unsolicited advertisements by e-mail. You may contact us with your opt-out request, along with the e-mail to which your request relates, by telephone at 1-877-540-6501, or by submitting your request to valeantorder@corpcomm.com. Opt-out requests will be honored within 10 business days of receipt. Please be sure to indicate the e-mail address to which your request relates and reason for opt-out.   ®/TMs are trademarks of Valeant Pharmaceuticals International, Inc. or its affiliates. Any other product or brand names and logos are the property of their respective owners.       Valeant Pharmaceuticals North America, Inc. 400 Somerset Corporate Blvd., Bridgewater, NJ 08807 USA   © 2015 Valeant Pharmaceuticals North America LLC.   DM/CLG/15/0011